FDA Greenlights Madrigal Pharmaceuticals’ Drug as First-Ever Treatment for Widespread NASH Liver Disease

FDA Greenlights Madrigal Pharmaceuticals' Drug as First-Ever Treatment for Widespread NASH Liver Disease

On Thursday, the Food and Drug Administration granted approval for the inaugural treatment targeting a prevalent and potentially fatal liver condition impacting millions globally. This landmark decision signifies a significant breakthrough for Madrigal Pharmaceuticals, distinguishing it from numerous larger competitors who have struggled or are still striving to penetrate this ...

Read More »